(-0.13%) 5 093.49 points
(0.03%) 38 253 points
(-0.16%) 15 903 points
(-1.38%) $82.69
(5.82%) $2.04
(0.25%) $2 353.00
(-0.32%) $27.45
(3.76%) $956.75
(-0.18%) $0.933
(-0.27%) $10.99
(-0.49%) $0.796
(1.69%) $93.43
-0.73% $ 2.72
Live Chart Being Loaded With Signals
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders...
Stats | |
---|---|
Tagesvolumen | 303 484 |
Durchschnittsvolumen | 142 922 |
Marktkapitalisierung | 116.44M |
EPS | $-0.460 ( 2023-11-08 ) |
Last Dividend | $1.512 ( 2023-10-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.563 |
ATR14 | $0.122 (4.49%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-13 | Siegall Clay B | Buy | 20 000 | Stock Option (Right to Buy) |
2023-12-13 | Siegall Clay B | Buy | 0 | |
2023-11-17 | Kulkarni Sandeep Chidambar | Buy | 4 000 | Common Stock |
2023-11-17 | Thiara Parvinder | Buy | 1 000 | Common Stock |
2023-10-27 | Castelein Caley | Buy | 15 800 | Common Stock |
INSIDER POWER |
---|
83.80 |
Last 89 transactions |
Buy: 5 796 448 | Sell: 603 108 |
Volumen Korrelation
Talaris Therapeutics, Korrelation
10 Am meisten positiv korreliert | |
---|---|
MRNS | 0.86 |
NPCE | 0.842 |
ALR | 0.818 |
SMED | 0.817 |
EPZM | 0.815 |
BIS | 0.808 |
THRY | 0.807 |
LTRY | 0.807 |
CNCE | 0.805 |
LVO | 0.802 |
10 Am meisten negativ korreliert | |
---|---|
WTBA | -0.867 |
EGAN | -0.854 |
ABST | -0.853 |
CRNT | -0.851 |
BNIXU | -0.85 |
PIXY | -0.834 |
CNDT | -0.832 |
FREQ | -0.823 |
VWE | -0.817 |
UPC | -0.813 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Talaris Therapeutics, Korrelation - Währung/Rohstoff
Talaris Therapeutics, Finanzdaten
Annual | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $0 (0.00 %) |
EPS: | $-16.66 |
FY | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $0 (0.00 %) |
EPS: | $-16.66 |
FY | 2021 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-2.26 |
FY | 2020 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
Talaris Therapeutics, Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$1.512 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $1.512 | 2023-10-19 |
Last Dividend | $1.512 | 2023-10-19 |
Next Dividend | $0 | N/A |
Payout Date | 2023-10-20 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $1.512 | -- |
Avg. Dividend % Per Year | 46.23% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $1.512 | 138.70% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.382 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.364 | 1.500 | -5.16 | -7.74 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 18.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 18.14 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 8.28 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00420 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -17.91 | 1.000 | -7.75 | -7.75 | [3 - 30] |
operatingCashFlowPerShareTTM | -12.28 | 2.00 | -4.09 | -8.19 | [0 - 30] |
freeCashFlowPerShareTTM | -12.47 | 2.00 | -6.24 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00444 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -82.75 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -1.667 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.202 | 1.000 | -0.121 | 0 | [1 - 100] |
returnOnEquityTTM | -0.364 | 2.50 | -3.32 | -7.74 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -12.47 | 2.00 | -4.16 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 55.58 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -12.28 | 2.00 | -4.09 | -8.19 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00392 | 1.500 | -3.36 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -2.25 |
Talaris Therapeutics,
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.